BRISBANE, Calif., Sept. 19 BiPar Sciences, Inc., aprivately held biopharmaceutical company developing novel cancer therapies,today announced that the company's Chairman of the Board G. Kirk Raab willassume the role of acting chief executive officer. The company is nowconducting a search for a permanent replacement for departing CEO Tom White, aco-founder of the firm. Mr. White will continue as a consultant and member ofthe board.
Mr. Raab was chief operating officer of Abbott Laboratories and CEO ofGenentech Inc. For the last 10 years he has been working as chairman and aconsultant to a number of new biotech companies.
"Tom has done a terrific job getting the company to this stage with ourlead product about to enter a robust series of Phase 2 clinical trials inseveral different cancers and a second compound advancing into the clinicearly next year," said Mr. Raab. "We will be searching for a CEO candidate whohas long-term commercial and development experience in oncology as we enter amore advanced stage of pipeline development at BiPar. In the meantime, I willbe involved on a day-to-day basis to keep these promising oncologyopportunities on track."
BiPar is developing multiple compounds designed to inhibit PARP 1(poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulatedin certain tumors. The company plans to begin Phase 2 trials for its leadcandidate BSI-201 later this year in three major cancers.
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stagebiopharmaceutical company developing and commercializing a novel class oftumor-selective drugs designed to meet the significant unmet needs of cancerpatients. The Company's lead product candidate is BSI-201, which is now inearly-stage clinical testing for advanced malignancies. The Company will beevaluating the potential of BSI-201 in multiple cancers and expects to fileinvestigational new drug applications on as many as two additional cancer drugcandidates in early 2008.
SOURCE BiPar Sciences Inc.